Immunotherapy and Vaccine Development for Viral Diseases
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Therapeutic Vaccines and Antibody Therapeutics".
Deadline for manuscript submissions: 31 August 2024 | Viewed by 258
Special Issue Editors
Interests: gene transcription in oxygen biology; autophagy; ubiquitin-proteosome system; cell signaling; influenza virus; dengue virus; program cell death; epigenetics; drug discovery and development; chemical biology
Interests: medical microbiology; antimicrobial resistance; infection control; respiratory viruses; investigation of microbial outbreaks
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Antiviral therapy through vaccines has saved countless lives and kept outbreaks and pandemics like smallpox, influenza and COVID-19 under check. The immune system can target any pathogen, yet we still become infected with novel infectious agents throughout our lives.
An exhaustive catalog of factors from hosts and pathogens that underpin whether an infection triggers or suppresses an immune response is needed to facilitate targeted therapy and reliable prognosis. In addition to reports on vaccine discovery and development, we seek basic research on the roles of viral proteins in immune response during infection and the cellular machineries these viral proteins regulate in reproduction, virulence and dormancy for improved vaccine and immunotherapies. Submissions on the discovery, development and reviews of biologics like the antibodies used in immunotherapy will also be considered for inclusion in this Special Issue. Reports on small molecules and natural products that facilitate immune activation or suppression during viral infections are also welcome.
Dr. Emmanuel Datan
Prof. Dr. Athanassios Tsakris
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antibodies
- vaccines
- immunotherapy
- virulence
- antivirals
- small molecules
- natural products
- virus
